Mereo BioPharma Group (LON:MPH) Reaches New 12-Month Low at $34.00

Mereo BioPharma Group PLC (LON:MPH)’s stock price reached a new 52-week low on Monday . The company traded as low as GBX 34 ($0.44) and last traded at GBX 37 ($0.48), with a volume of 12241 shares. The stock had previously closed at GBX 37 ($0.48).

The company has a debt-to-equity ratio of 55.68, a quick ratio of 2.18 and a current ratio of 2.32. The business has a 50-day simple moving average of GBX 53.30 and a two-hundred day simple moving average of GBX 67.49. The stock has a market cap of $36.25 million and a price-to-earnings ratio of -0.86.

In related news, insider Peter J. Fellner acquired 23,800 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were bought at an average price of GBX 60 ($0.78) per share, for a total transaction of £14,280 ($18,659.35). Also, insider Denise Scots-Knight acquired 13,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were bought at an average price of GBX 59 ($0.77) per share, for a total transaction of £7,965 ($10,407.68).

About Mereo BioPharma Group (LON:MPH)

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Further Reading: What is the Hang Seng index?  

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.